Acurx Pharmaceuticals Inc ACXP

Healthcare Biotechnology

Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme. Phase II clinical data validate the efficacy of its lead antibiotic candidate, as well as pol IIIC as an appropriate bacterial target.

NDAQ:ACXP - Post by User

Acurx Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by whytestockson Feb 16, 2024 4:15pm

47 Views

Post# 35885022

New to The Street Airs Episode 556 Featuring Five Corporate

News; $ACXP New to The Street Airs Episode 556 Featuring Five Corporate Interviews, Broadcast on the FOX Business Network Monday, February 19, 2024, at 10:30 PM PTNEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- FMW Media Works Corp.'s New to the Street, a nationally broadcasted business television production, announces airing Episode 556 on the FOX Business Network Monday, February 19, 2024, at 10:30 PM PT. New to The Street's Episode 556 line-up...ACXP - New to The Street Airs Episode 556 Featuring Five Corporate Interviews, Broadcast on the FOX Business Network Monday, February 19, 2024, at 10:30 PM PT

<< Previous

Bullboard Posts

Next >>

Nextech3D.ai receives purchase order from blue-chip customer